Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Post by Jefferam1on Mar 28, 2018 11:57am

136 Views

Post# 27795183

Congrats to all those who called a sub 0.40 price - wow

I can't even begin to explain what is happening here. I know pull backs happen, but sub 40?
I mean being able to buy in today after amazing results at a lower price then March 12 before the results and working on rumor only.... this is bewildering.
Never thought I'd see it back down to this. Glad I took some profits 0.75 to be in the positive.
Now that I have no cost in it, I'll just sit and wait. Worst case scenario I lose a few hundred thousand dollars in profit. Best case scenario I wait long enough and make a few million.
I guess it's time to stop watching this stock daily. See you all in a few months.
GLTA

Bullboard Posts

Investor’s corner: Solving chronic pain in dogs – A significant market opportunity